2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

227 citing papers in PubMed, 10 syntheses or guidelines pooled it.

1. Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.Cardiovascular toxicology · 2026
   Pooled it
2. Cardioprotective role of antihypertensive treatment in chemotherapy-induced cardiotoxicity: umbrella review of meta-analyses of randomised controlled trials.Open heart · 2026
   Pooled it
3. Time-dynamic perspectives on cancer therapy-related cardiotoxicity: a systematic review and time-course evidence synthesis for multibiomarker monitoring.Frontiers in cardiovascular medicine · 2026
   Pooled it
4. Fatal Myocarditis Following Adjuvant Immunotherapy: A Case Report and Literature Review.International journal of molecular sciences · 2025
   Pooled it
5. Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials.Breast cancer research and treatment · 2025
   Pooled it
6. Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review.Frontiers in immunology · 2025
   Pooled it
7. Chemotherapy cardiotoxicity research in cancer patients: a bibliometric and visual analysis (1994-2024).Frontiers in oncology · 2025
   Pooled it
8. International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.Transplantation and cellular therapy · 2024
   Guideline
9. Corticosteroid-resistant immune-related adverse events: a systematic review.Journal for immunotherapy of cancer · 2024
   Pooled it
10. Role and efficacy of capecitabine in the anthracycline-free regimen in breast cancer patients: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2023
    Pooled it
11. Real-time deep learning-based image guiding and automated left ventricular measurements to reduce test-retest variability.Open heart · 2025
    Trial
12. Evaluating the role of montelukast on doxorubicin-induced cardiotoxicity in breast cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
13. Randomized, Placebo-Controlled, Triple-Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline-Based Cancer Therapy.Journal of the American Heart Association · 2025
    Trial
14. Effectiveness of a Cardiovascular Health Electronic Health Record Application for Cancer Survivors in Community Oncology Practice: Results From WF-1804CD.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
15. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.Medicina (Kaunas, Lithuania) · 2023
    Trial
16. Effectiveness of self-management interventions in reducing cancer treatment-related cardiotoxicity in breast cancer survivors: A systematic review.Asia-Pacific journal of oncology nursing · 2026
    Review
17. Complex cardiac overlap: immune checkpoint inhibitor myocarditis in hypertrophic obstructive cardiomyopathy with subsequent NSTEMI.Cardio-oncology (London, England) · 2026
    Article
18. Discordance between left ventricular ejection fraction and global longitudinal strain during routine cardio-oncology surveillance.Cardiovascular ultrasound · 2026
    Observational
19. Dyslipidaemias in cancer patients.European heart journal · 2026
    Review
20. Longitudinal Changes in QTc Interval in Cancer Patients After the Initiation of Systemic Therapy: Analysis of the ONCOECHO Study Cohort.Cancers · 2026
    Article

167 more citing papers are in PubMed but not listed here.

Corrections and comments

• Commented on by
  The ESC cardio-oncology 2022 guidelines; the ball is in our court.2023
• Erratum issued
  Erratum: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC).2023

Authors and funding

31 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as